Management of Graves’ hyperthyroidism: present and future

References

• Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724–734.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hegedus L. Graves’ disease. N Engl J Med. 2016;375(16):1552–1565.
   PubMed Web of Science ®Google Scholar
• Kahaly GJ. Management of Graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab. 2020;105(12):3704–3720.
   PubMed Web of Science ®Google Scholar
• Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves’ disease. Immunol Res. 2012;54(1–3):191–203.
   PubMed Web of Science ®Google Scholar
• Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98(4):1443–1449.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest. 2014;37(8):691–700.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Masiello E, Magri F, et al. The phenotype of newly diagnosed Graves’ disease in Italy is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest. 2016;39(12):1445–1451.
   PubMed Web of Science ®Google Scholar
• Ippolito S, Cusini C, Lasalvia P, et al. Changes in newly diagnosed Graves’ disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. J Endocrinol Invest. 2021;44(8):1707–1718.
   PubMed Web of Science ®Google Scholar
• Pujol A, Gomez L-A, Gallegos C, et al. Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-CoV2 vaccination: from Graves’ disease to silent thyroiditis. J Endocrinol Invest. 2021 Nov 18. DOI:https://doi.org/10.1007/s40618-021-01707-0. Online ahead of print.
   Google Scholar
• Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ after COVID-19. J Endocrinol Invest. 2020;43(10):1527–1528.
   PubMed Web of Science ®Google Scholar
• Lanzolla G, Marcocci C, Marinò M. Graves’ disease and Graves’ orbitopathy following COVID-19. J Endocrinol Invest. 2021;44(9):2011–2012.
   PubMed Web of Science ®Google Scholar
• Jimenez-Blanco S, Pla-Peris B, Marazuela M. COVID-19: a cause of recurrent Graves’ hyperthyroidism? J Endocrinol Invest. 2021;44(2):387–388.
   PubMed Web of Science ®Google Scholar
• Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two cases of Graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. 2021;31(9):1436–1439.
   PubMed Web of Science ®Google Scholar
• Zettinig G, Krebs M. Two further of Graves’ disease following SARS-Cov-2 vaccination. J Endocrinol Invest. 2022;45(1):227.228.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Chiovato L, Vitti P. Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any). J Endocrinol Invest. 2016;39(10):1105–1114.
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Bartalena L, Hegedus L, et al. European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167–186. 2018.
   PubMed Web of Science ®Google Scholar
• Ross D, Burch HB, Cooper DS, et al. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1420.
   PubMed Web of Science ®Google Scholar
• van Kinshot CMJ, Soekhai VR, de Bekker-grob EW, et al. Preference of patients and clinicians for treatment of Graves’ disease: a discrete choice experiment. Eur J Endocrinol. 2021;184(6):803–812.
   PubMedGoogle Scholar
• Bartalena L, Burch HB, Burman KD, et al. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol. 2016;84(1):115–120.
   PubMed Web of Science ®Google Scholar
• Brito JP, Schilz S, Singh Ospina N, et al. Antithyroid drugs – the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid. 2016;26(8):1144–1145.
   PubMed Web of Science ®Google Scholar
• Burch HD, Cooper DS. Antithyroid drug therapy: 70 years later. Eur J Endocrinol. 2018;179(5):R261–R274.
   PubMed Web of Science ®Google Scholar
• Chen P-L, Shih S-R, Wang P-W, et al. Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association studies. Nat Commun. 2015;6(1):8633.
   PubMedGoogle Scholar
• Hallberg P, Eriksson N, Ibanez L, et al. Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol. 2016;4(6):507–516.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li X, Yang Q, et al. Granulocyte—colony-stimulating factor effectively shortens recovery duration in anti-thyroid drug-induced agranulocytosis: a systematic review and meta-analysis. Front Endocrinol. 2019;10:789.
   PubMed Web of Science ®Google Scholar
• Takata K, Subota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid. 2009;19(6):559–563.
   PubMed Web of Science ®Google Scholar
• Rivkees SA. Controversies in the management of Graves’ disease in children. J Endocrinol Invest. 2016;39(11):1247–1257.
   PubMed Web of Science ®Google Scholar
• Cin MO, Gursoy A, Morris Y, et al. Prevalence and clinical significance of antineutrophyl cytoplasmic antibody in Graves’ patients treated with propylthiouracil. Int J Clin Pract. 2009;63(2):299–302.
   PubMed Web of Science ®Google Scholar
• Brix TH, Lund LC, Henriksen DP, et al. Methimazole and risk of acute pancreatitis. Lancet Diabetes Endocrinol. 2020;8(3):187–189.
   PubMed Web of Science ®Google Scholar
• Pecere A, Caputo M, Sarro A, et al. Methimazole treatment and risk of acute pancreatitis: a population-based cohort study. J Clin Endocrinol Metab. 2020;105(12):e4527–e4530.
   Web of Science ®Google Scholar
• Guo JY, Chang C-L, Chen -C-C. Association between thionamides and acute pancreatitis: a case-control study. Thyroid. 2020;30(11):1574–1578.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Piantanida E, Tanda ML. Methimazole treatment and acute pancreatitis: both caution and reassurance are needed. J Clin Endocrinol Metab. 2020;105(12):e4967–e4969.
   Web of Science ®Google Scholar
• Andersen SL, Olsen J, Wu CS, et al. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98(11):4373–4381.
   PubMed Web of Science ®Google Scholar
• Andersen SL, Olsen J, Wu CS, et al. Severity of birth defects after propylthiouracil exposure in early pregnancy thyroid. Thyroid: Official Journal of the American Thyroid Association. 2014;24(10):1533–1540.
   PubMed Web of Science ®Google Scholar
• Abraham P, Avenell A, Park CM, et al. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol. 2005;153(4):489–498.
   PubMed Web of Science ®Google Scholar
• Zarkovic M, Wiersinga WM, Perros P, et al. Antithyroid drugs in Graves’ hyperthyroidism: differences between “block and replace” and “titration regimes in frequency of euthyroidism and Graves’ orbitopathy during treatment. J Endocrinol Invest. 2021;44(2):371–378.
   PubMed Web of Science ®Google Scholar
• Azizi F, Abdi H, Amouzegar A. Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial. BMC Endocr Disord. 2021;21(1):16.
   PubMed Web of Science ®Google Scholar
• Azizi F, Malboosdaf R. Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid. 2017;27(10):1223–1231.
   PubMed Web of Science ®Google Scholar
• Azizi F, Malboosbaf R. Safety of long-term antithyroid drug treatment? A systematic review. J Endocrinol Invest. 2019;42(11):1273–1283.
   PubMed Web of Science ®Google Scholar
• Mazza E, Carlini M, Flecchi D, et al. Long-term follow-up of patients with hyperthyroidism due to Graves’ disease: comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole dose: a retrospective study. J Endocrinol Invest. 2008;31(10):866–872.
   PubMed Web of Science ®Google Scholar
• Laurberg P, Berman DC, Andersen S, et al. Sustained control of Graves’ hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with Graves’ orbitopathy. Thyroid. 2011;21(9):951–956.
   PubMed Web of Science ®Google Scholar
• Elbers L, Mourits M, Wiersinga W. Outcome of very-long treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy. Thyroid. 2011;21(3):279–283.
   PubMed Web of Science ®Google Scholar
• Sundaresh V, Brito JP, Thapa P, et al. Comparative effectiveness of treatment choices for Graves’ hyperthyroidism: a historical cohort study. Thyroid. 2017;27(4):497–505.
   PubMed Web of Science ®Google Scholar
• Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment Thyroid. Thyroid: Official Journal of the American Thyroid Association. 1997;7(3):369–375.
   PubMed Web of Science ®Google Scholar
• Piantanida E, Lai A, Sassi L, et al. Outcome prediction of treatment of Graves’ hyperthyroidism with antithyroid drugs. Horm Metab Res. 2015;47(10):767–772.
   PubMed Web of Science ®Google Scholar
• Vos XG, Endert E, Zwinderman K, et al. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2016;101(4):1381–1389.
   PubMed Web of Science ®Google Scholar
• Struja T, Kaeslin M, Boesiger F, et al. External validation of the GREAT score to predict relapse risk in Graves’ disease: results of a multicenter, retrospective study with 741 patients. Eur J Endocrinol. 2017;176(4):413–419.
   PubMed Web of Science ®Google Scholar
• Masiello E, Veronesi G, Gallo D, et al. Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest. 2018;41(12):1425–1432.
   PubMed Web of Science ®Google Scholar
• Laurberg P, Andersen SL. Pregnancy and the incidence, diagnosing and therapy of Graves’ disease. Eur J Endocrinol. 2016;175(5):R219–R230.
   PubMed Web of Science ®Google Scholar
• Rotondi M, Cappelli C, Pirali B, et al. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab. 2008;93(10):3985–3988.
   PubMed Web of Science ®Google Scholar
• Rabon S, Burton AM, White PC. Graves’ disease in children: long-term outcomes of medical therapy. Clin Endocrinol (Oxf). 2016;85(4):632–635.
   PubMed Web of Science ®Google Scholar
• Vigone MC, Peroni E, Di Frenna M, et al. “Block and replace” treatment in Graves’ disease: experience in a cohort of pediatric patients. J Endocrinol Invest. 2020;43(5):595–600.
   PubMed Web of Science ®Google Scholar
• Biondi B, Cooper DS. Subclinical hyperthyroidism. N Engl J Med. 2018;378(25):2411–2419.
   PubMed Web of Science ®Google Scholar
• Khan SR, Chaker L, Ruiter R, et al. Thyroid function and cancer risk: the Rotterdam study. J Clin Endocrinol Metab. 2016;101(12):5030–5036.
   PubMed Web of Science ®Google Scholar
• Zhyzhneuskaya S, Addison C, Tsatlidis V, et al. The natural hostory of subclinical hyperthyroidism in Graves’ disease: the rule of thirds. Thyroid. 2016;26(6):765–769.
   PubMed Web of Science ®Google Scholar
• Aung ET, Zammitt NN, Dover AR, et al. Predicting outcomes and complications following radioiodine therapy in Graves’ thyrotoxicosis. Clin Endocrinol. 2019;90(1):192–199.
   PubMed Web of Science ®Google Scholar
• Nygaard B, Hegedus L, Gervil M, et al. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves’ disease. J Intern Med. 1995;238(6):491–497.
   PubMed Web of Science ®Google Scholar
• Vannucchi G, Covelli D, Campi I, et al. Prevention of orbitopathy by intravenous steroid prophylaxis in short duration Graves’ disease patients undergoing radioiodine ablation: a prospective randomized control trial study. Thyroid. 2019;29(12):1828–1833.
   PubMed Web of Science ®Google Scholar
• Franklyn JA, Maisonneuve P, Sheppard MC, et al. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338(11):712–718.
   PubMed Web of Science ®Google Scholar
• Metso S, Jaatinen P, Huhtala H, et al. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92(6):2190–2196.
   PubMed Web of Science ®Google Scholar
• Giesecke P, Frykman V, Wallin G, et al. All-cause and cardiovascular mortality risk after surgery versus radioiodine treatment for hyperthyroidism. Br J Surg. 2018;105(3):279–286.
   PubMed Web of Science ®Google Scholar
• Ryodi E, Metso S, Huhtala H, et al. Cardiovascular morbidity and mortality after treatment with either radioactive iodine or thyroidectomy. Thyroid. 2018;28(9):1111–1120.
   PubMed Web of Science ®Google Scholar
• Boelaert K, Maisonneuve P, Torlinska B, et al. Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab. 2013;98(5):1869–1882.
   PubMed Web of Science ®Google Scholar
• Okosieme OE, Taylor PN, Evans C, et al. Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol. 2019;7(4):278–287.
   PubMed Web of Science ®Google Scholar
• Lillevang-Johansen M, Abrahamsen B, Jorgensen HL, et al. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk. Thyroid. 2019;29(3):332–340.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Piantanida E, Tanda ML. Can a patient-tailored approach for Graves’ disease reduce mortality? Lancet Diabetes Endocrinol. 2019;7(4):245–246.
   PubMed Web of Science ®Google Scholar
• Kim BW. Does radioactive iodine therapy for hyperthyroidism cause cancer? J Clin Endocrinol Metab. 2022;107:e448–e457. DOI:https://doi.org/10.1210/clinem/dgab700.
   PubMed Web of Science ®Google Scholar
• Kitahara CM, Berrington de Gonzalez A, Bouville A, et al. Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med. 2019;179(8):1034–1042.
   PubMed Web of Science ®Google Scholar
• Kitahara CM, Preston DL, Sosa JA, et al. Association of radioactive iodine, antithyroid drug, and surgical treatments with solid cancer mortality in patients with hyperthyroidism. JAMA Network Open. 2020;3(7):e209660.
   PubMed Web of Science ®Google Scholar
• Gronich N, Lavi I, Rennert G, et al. Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study. Thyroid. 2020;30(2):243–250.
   PubMed Web of Science ®Google Scholar
• Yan D, Chen C, Yan H, et al. Mortality risk after radioiodine therapy for hyperthyroidism: a systematic review and meta-analysis. Endocr Pract. 2021;27(4):362–369.
   PubMed Web of Science ®Google Scholar
• Shim SR, Kitahara CM, Cha ES, et al. Cancer risk after radioactive iodine treatment for Graves’ hyperthyroidism: a systematic review and meta-analysis. JAMA Network Open. 2021;4(9):e2125072.
   PubMed Web of Science ®Google Scholar
• Taylor PN, Okosieme OE, Chatterjee K, et al. Joint statement from the Society for Endocrinology and the British Thyroid Association regarding “Association of radioactive thyroid treatment with cancer mortality in patients with hyperthyroidism. Clin Endocrinol (Oxf). 2020;92(3):266–267.
   PubMed Web of Science ®Google Scholar
• Lutterman SL, Zwaveling-Soonavala N, Verberne HJ, et al. The efficacy and short- and long-term side effects of radioactive iodine treatment in pediatric Graves’ disease: a systematic review. Eur Thyroid J. 2021;10(5):353–363.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338(2):73–78.
   PubMed Web of Science ®Google Scholar
• Traisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves’ ophthalmopathy with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94(10):3700–3707.
   PubMed Web of Science ®Google Scholar
• Lai A, Sassi L, Compri E, et al. Lower dose prednisone prevents exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab. 2010;95(3):1333–1337.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43–G67.
   PubMed Web of Science ®Google Scholar
• Rosetti S, Tanda ML, Veronesi G, et al. Oral steroid prophylaxis after radioactive iodine treatment for Graves’ disease is not only effective, but also safe. J Endocrinol Invest. 2020;43(3):381–383.
   PubMed Web of Science ®Google Scholar
• Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549–4558.
   PubMed Web of Science ®Google Scholar
• Sosa JA, Mehta PJ, Wang TS, et al. A population-based study of outcomes from thyroidectomies in aging Americans: at what cost? J Am Coll Surgeons. 2008;206(6):1097–1105.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States. World J Surg. 2010;34(6):1261–1264.
   PubMed Web of Science ®Google Scholar
• Dionigi G, Dralle H, Materazzi G, et al. Happy 20th birthday to minimally invasive video-assisted thyroidectomy! J Endocrinol Invest. 2020;43(3):385–388.
   PubMed Web of Science ®Google Scholar
• Rubin SJ, Park JH, Pearce EN, et al. Vitamin D status as a predictor of post-operative hypocalcemia after thyroidectomy. Otolaryngol Head Neck Surg. 2020;163(3):501–507.
   PubMed Web of Science ®Google Scholar
• Ramouz A, Hosseini M, Hosseinzadeh SS, et al. Preoperative vitamin D supplementation in patients with vitamin D deficiency undergoing total thyroidectomy. Am J Med Sci. 2020;360(2):146–152.
   PubMed Web of Science ®Google Scholar
• Watt T, Groenvold M, Rasmussen AK, et al. Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol. 2006;154(4):501–510.
   PubMed Web of Science ®Google Scholar
• Ferlov-Schwensen C, Brix TH, Hegedus L. Death by suicide in Graves’ disease and Graves’ orbitopathy: a nationwide Danish register study. Thyroid. 2017;27(12):1475–1480.
   PubMed Web of Science ®Google Scholar
• Gerding MN, Terwee CB, Dekker FW, et al. Quality of life in patient with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid. 1997;7(6):885–889.
   PubMed Web of Science ®Google Scholar
• Ponto KA, Merkesdal S, Hommel G, et al. Public health relevance of Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98(1):145–152.
   PubMed Web of Science ®Google Scholar
• Elberling TV, Rasmussen AK, Feldt-Rasmussen U, et al. Impaired health-related quality of life in Graves’ disease. A prospective study. Eur J Endocrinol. 2004;151(5):549–555.
   PubMed Web of Science ®Google Scholar
• Cramon P, Winther KH, Watt T, et al. Quality of life impairments persist six months after treatment of Graves’ hyperthyroidism and toxic nodular goiter: a prospective cohort study. Thyroid. 2016;(8):1010–1018.
   PubMed Web of Science ®Google Scholar
• Ljunggren J JG, Torring O, Wallin G, et al. Quality of life aspects and costs of Graves’ hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid. 1998;8(8):653–659.
   PubMed Web of Science ®Google Scholar
• Torring O, Watt T, Sjolin G, et al. Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for Graves’ hyperthyroidism: a long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status survey. Thyroid. 2019;29(3):322.331.
   Web of Science ®Google Scholar
• Gunn AH, Frisco N, Thomas SM, et al. Patient-reported outcomes following total thyroidectomy for Graves’ disease. Thyroid. 2022;32(1):1–11.
   PubMedGoogle Scholar
• Conaglen HM, Tamatea JAV, Conaglen JV, et al. Treatment choice, satisfaction and quality of life in patients with Graves’ disease. Clin Endocrinol. 2018;88(6):977–984.
   PubMed Web of Science ®Google Scholar
• Genain CP, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a nonhuman primate. Science. 1996;274(5275):2054–2057.
   PubMedGoogle Scholar
• Chataway J, Martin K, Barrell K, et al. Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis. Neurology. 2018;90(11):e955–e962.
   PubMed Web of Science ®Google Scholar
• Jansson L, Vrolix K, Jahraus A, et al. Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice. Endocrinology. 2018;159(9):3446–3457.
   PubMed Web of Science ®Google Scholar
• Pearce SHS, Dayan C, Wraith DC, et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves’ hyperthyroidism: a phase I study. Thyroid. 2019;29(7):1003–1011.
   PubMed Web of Science ®Google Scholar
• Furmaniak J, Sanders J, Young S, et al. In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking monoclonal autoantibody (K1-70). Autommun Highlights. 2012;3(1):19–25.
   PubMedGoogle Scholar
• Ryder M, Wentworth M, Algeciras-Schimnich A, et al. Blocking the thyrotropin receptor with K1-70 in a patient with follicular thyroid cancer, Graves’ disease, and Graves’ ophthalmopathy. Thyroid. 2021;31(10):1597–1602.
   PubMed Web of Science ®Google Scholar
• Furmaniak J, Sanders J, Sanders P, et al. TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves’ disease and Graves’ orbitopathy – results from a phase I clinical trial. Clin Endocrinol. 2022. DOI:https://doi.org/10.1111/cen.14681.
   Google Scholar
• Neumann S, Nir EA, Eliseeva E, et al. A selective TSH receptor antagonists inhibits stimulation of thyroid function in female mice. Endocrinology. 2014;155(1):310–314.
   PubMed Web of Science ®Google Scholar
• Latif R, Realubit RB, Karan C, et al. TSH receptor signaling abrogation by a novel small molecule. Front Endocrinol. 2016 Sep 27;130.https://doi.org/10.3389/fendo.2016.00130.
   Google Scholar
• Marcinkowski P, Hoyer I, Specker E, et al. A new highly thyrotropin- receptor-selective small-molecule antagonist with potential for the treatment of Graves’ orbitopathy. Thyroid. 2019;29(1):111–123.
   PubMed Web of Science ®Google Scholar
• Lane C, Cheetham TD, Perros P, et al. New therapeutic horizons for Graves’ hyperthyroidism. Endocr Rev. 2020;41(6):1–12.
   Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613–620.
   PubMed Web of Science ®Google Scholar
• El Fassi D, Nielsen CH, Bonnema SJ, et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled placebo study. J Clin Endocrinol Metab. 2007;92(5):1769–1772.
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Toes RE, Sepers J, et al. Rituximab in relapsing Graves’ disease, a phase II study. Eur J Endocrinol. 2008;159(5):615–619.
   Web of Science ®Google Scholar
• El Fassi D, Clemmensen O, Nielsen CH, et al. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves’ disease. J Clin Endocrinol Metab. 2007;92(10):3762–3763.
   PubMed Web of Science ®Google Scholar
• Cheetham TD, Cole M, Abinun M, et al. Adjuvant rituximab – exploratory trial in young people with Graves disease. J Clin Endocrinol Metab. 2021. Doi:https://doi.org/10.1210/clinem/dgab763. online ahead of print.
   Google Scholar
• Van Lieshout JM, Mooij CF, van Trotsenburg AFP, et al. Methimazole-induced remission rates in pediatric Graves’ disease: a systematic review. Eur J Endocrinol. 2021;185(2):219–229.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496–1502.
   PubMed Web of Science ®Google Scholar
• El Fassi D, Nielsen CH, Junker P, et al. Systemic adverse events following rituximab therapy in patients with Graves’ disease. J Endocrinol Invest. 2011;34(7):163–167.
   PubMed Web of Science ®Google Scholar
• Berger JR, Malik V, Lacey S, et al. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol. 2018;24(3):323–331.
   PubMed Web of Science ®Google Scholar
• Vannucchi G, Covelli D, Currò N, et al. Serum BAFF concentrations in patients with Graves’ disease and orbitopathy before and after immunosuppressive therapy. J Clin Endocrinol Metab. 2012;97(5):E755–E759.
   PubMed Web of Science ®Google Scholar
• Wang X, Huang J, Zhang A, et al. Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves’ disease. BMC Endocrine Disord. 2021;21(1):88.
   PubMed Web of Science ®Google Scholar
• Ristov J, Espei P, Ulrich P, et al. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant. 2018;18(12):2895–2904.
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Stan MN, Frommer L, et al. A novel anti-CD40 monoclonal antibody, iscalimab, for control of Graves’ hyperthyroidism – a proof-of-concept trial. J Clin Endocrinol Metab. 2020;105(3):696–704.
   Web of Science ®Google Scholar
• Neag EJ, Smith TJ. 2021 update on thyroid-associated ophthalmopathy. J Endocrinol Invest. 2021 Aug 20. DOI: https://doi.org/10.1007/s40618-021-01663-9. online ahead of print.
   Google Scholar
• Smith TJ. Teprotumumab as a novel therapy for thyroid-associated ophthalmopathy. Front Endocrinol. 2020 Dec 17;11:610337.
   PubMed Web of Science ®Google Scholar
• Wiersinga WM. Graves’ disease: can it be cured? Endocrinol Metab. 2019;34(1):29–38.
   Google Scholar
• Somwaru LL, Arnold AM, Joshi N, et al. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab. 2009;94(4):1342–1345.
   PubMed Web of Science ®Google Scholar
• Lillevang-Johansen M, Abrahamsen B, Jorgensen HL, et al. Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. Eur J Endocrinol. 2019;180(6):407–416.
   PubMed Web of Science ®Google Scholar